Episode Details
Back to Episodes2026 Could Be a Defining Year for POLB 001 and Oral GLP-1
Episode 2382
Published 1 week ago
Description
Poolbeg Pharma CEO Jeremy Skillington discusses progress across POLB 001, including regulatory clearance, IP protection, US payer research and the path towards interim clinical data in cancer immunotherapy-induced CRS. He also updates investors on the company’s cash runway, partnering strategy and the potential commercial opportunity in oral GLP-1 therapies.